Low serum calprotectin levels correlate with the presence of biological drugs after the first year of treatment in patients with rheumatoid arthritis

Click to increase image sizeClick to decrease image size

Correction Statement

This article has been republished with minor changes. These changes do not impact the academic content of the article.

Acknowledgments

We are grateful to all the rheumatologists and nurses of the Daycare Department for Biologics, the laboratory technicians of the Immunological Unit and the Spanish Society of Rheumatology who have corrected the manuscript.

Disclosure statement

Chamaida Plasencia-Rodriguez has received speaking fees or funding for research projects from Pfizer, Lilly, Novartis, and Roche. Victoria Navarro-Compan has received speaking fees or funding for research projects and for attending congresses from AbbVie, BMS, Lilly, MSD, Novartis, Pfizer, Roche and UCB; Dora Pascual-Salcedo has received speaking fees of Abbvie, Pfizer, Takeda, Menarini and Grifols. Alejandro Balsa has received honoraria as an advisor and speaker and grants from Pfizer, Abbvie, Roche, UCB, Gilead, Sandoz, Novartis,Lilly, Nordic, Sanofi and Amgen.

Additional information

Funding

This work has been partially financed with a grant without restrictions (BECA MSD-2016) of the "SORCOM" (Society of Rheumatology of the Madrid's community).